The Ethics of Cancer Drug Pricing

This chapter explores the ethical dilemmas and complexities of pharmaceutical pricing for cancer treatments. It examines the impact of monopolistic practices, Medicare's inability to negotiate prices, and the influence of social pressures on drug costs. The discussion highlights the conflicts of interest that arise between pharmaceutical companies, healthcare professionals, and patient advocacy groups, calling for a critical reevaluation of the current system.